Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...
Transitioning from IV to Sub-Q Darzalex Faspro significantly improved Kennedy's quality of life, reducing treatment time and enhancing productivity. The FDA approved Darzalex Faspro for high-risk ...
In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that could put some pressure on CAR T-cell therapies, including the company’s own ...
In patients with clear cell renal cell carcinoma (ccRCC), there are a number of second-line options to consider. Sumanta K. Pal, MD, FASCO, professor, Department of Medical Oncology & Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results